ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
News
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
US green light for AZ’ Lokelma
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia – elevated potassium levels in the blood – in adult patients.
Data show ‘enduring’ benefits of GSK’s Nucala
GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.
EMA confirms risks of MS drug Zinbryta
The European Medicines Agency has concluded that the risks linked with use of Biogen and AbbVie’s multiple sclerosis drug Zinbryta outweigh its benefits.
AI should be used to detect chronic disease, says PM
Prime Minister Theresa May has revealed new plans to prevent thousands of cancer deaths and improve the detection of chronic diseases through greater use of artificial intelligence.
US OK’s first-in-class drug Aimovig for migraine prevention
Amgen and Novartis’ Aimovig has become the first anti-CGRP therapy to win regulatory clearance in the US, winning approval for migraine prevention.
International Clinical Researcher of the Year – Winners announced
The 19th International Clinical Researcher of the Year took place at the Millennium Gloucester Hotel in London’s Kensington last night, hosted by BBC news presenters Charlie Stayt and Ros Atkins.
Janssen pulls plug on Alzheimer’s candidate
Safety concerns have prompted Janssen to pull the plug on a development programme testing the BACE inhibitor atabecestat for Alzheimer’s disease.
Trials show benefit of ‘on demand’ use of AZ’ asthma inhaler
AstraZeneca has unveiled data from two Phase III trials showing the benefit of using Symbicort Turbuhaler as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma.
Generic competition hits AZ’ first-quarter sales
AstraZeneca’s first-quarter performance has taken a hit from generic competition to Crestor, but the firm says the results are no surprise and that it will swing back into the black this year.
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
NICE backs Roche’s Tecentriq for pre-treated bladder cancer
Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with advanced, pre-treated bladder cancer, following a nod from cost-regulators.
Dupixent trial hits targets in adolescent atopic dermatitis
A late-stage study of Sanofi and Regeneron’s Dupixent in adolescents with atopic dermatitis has met its key targets, paving the way for a regulatory submission for drug targeting this younger patient group in the third quarter.
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
